Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Human Epidermal Growth Factor Receptor 2 (HER2)”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT01367002
What this trial is testing

Evaluation of Carboplatin/Paclitaxel With and Without Trastuzumab (Herceptin) in Uterine Serous Cancer

Who this might be right for
Endometrial Cancer
Yale University 61
Early research (Phase 1)Study completedNCT03242239
What this trial is testing

A Comparing Study Between ALT02(Trastuzumab Biosimilar) and Herceptin® in Healthy Subjects

Who this might be right for
Healthy
Alteogen, Inc. 105
Testing effectiveness (Phase 2)Study completedNCT01730612
What this trial is testing

ImmunoTEP au 68-Ga- IMP-288 for Patients With a Recurrence of HER2 Negative Breast Carcinoma Expressing CEA

Who this might be right for
HER2 Negative Breast Carcinoma Expressing CEA
Nantes University Hospital 23
Not applicableEnded earlyNCT01187381
What this trial is testing

An Observational Study of the Mean Duration of Trastuzumab (Herceptin) Treatment in Participants With Early or Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer

Who this might be right for
Breast Cancer
Hoffmann-La Roche 250
Testing effectiveness (Phase 2)UnknownNCT05134519
What this trial is testing

RC48 for Neoadjuvant Chemotherapy of HER2 Positive Breast Cancer

Who this might be right for
Breast CancerHER2-positive Breast Cancer
Xijing Hospital 20
Not applicableNot Yet RecruitingNCT07553234
What this trial is testing

Study to Understand Relationship Between Gut Health and Toxicities of Hormonal Breast Cancer Treatment

Who this might be right for
Breast Cancer
University of Chicago 20
Post-approval studies (Phase 4)Not Yet RecruitingNCT07093931
What this trial is testing

Efficacy and Safety of Lobaplatin and Carboplatin as Neoadjuvant Therapy in HER-2 Positive Breast Cancer

Who this might be right for
Breast Cancer
Shandong Cancer Hospital and Institute 468
Testing effectiveness (Phase 2)Active Not RecruitingNCT05715931
What this trial is testing

Perioperative Chemotherapy Plus Trastuzumab Plus Toripalimab in HER2 Positive Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma

Who this might be right for
Adenocarcinoma of the StomachAdenocarcinoma of Esophagogastric JunctionHER2-positive Gastric Cancer
Yu jiren 30
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06888037
What this trial is testing

Fruquintinib Combined With PD-1 Inhibitor as First-line Maintenance Therapy for Advanced Gastric Cancer

Who this might be right for
Gastric AdenocarcinomaGEJ AdenocarcinomaFirst-line Therapy+3 more
Ruijin Hospital 55
Not applicableStudy completedNCT05132101
What this trial is testing

Analysis of the Real-world Prescription Pattern of Palbociclib Combination Therapy With Aromatase Inhibitor as a First Line Therapy in Metastatic Breast Cancer Patients Using the National Health Insurance Claims Data in South Korea

Who this might be right for
Metastatic Breast Cancer
Pfizer 2,758
Testing effectiveness (Phase 2)UnknownNCT04380012
What this trial is testing

A Clinical Study of Pyrotinib in Patients With HER2-positive Advanced Colorectal Cancer

Who this might be right for
Colorectal Cancer
Second Affiliated Hospital, Zhejiang University, School of Medicine 40
Testing effectiveness (Phase 2)UnknownNCT05044988
What this trial is testing

HS-10342 in Chinese Patients With HR+/HER2- Advanced and/or Metastatic Breast Cancer

Who this might be right for
HR+/HER2- Advanced and/or Metastatic Breast Cancer
Jiangsu Hansoh Pharmaceutical Co., Ltd. 20
Testing effectiveness (Phase 2)Active Not RecruitingNCT06172127
What this trial is testing

PHESGO Maintenance After T-DXd Short Induction for HER2+ Unresectable Locally Recurrent or Metastatic Breast Cancer

Who this might be right for
HER2-positive Breast Cancer
MedSIR 165
Testing effectiveness (Phase 2)Looking for participantsNCT06516289
What this trial is testing

Neoadjuvant Treatment of gBRCA-Mutated HER2-Negative Breast Cancer With HRS-1167 and Famitinib ± Camrelizumab

Who this might be right for
BRCA-Mutated Breast CarcinomaHER2-negative Breast Cancer
Fudan University 130
Testing effectiveness (Phase 2)Looking for participantsNCT06254690
What this trial is testing

The Dosing Regimen of Pyrotinib in HER2-positive Advanced First-line Breast Cancer: a Phase II Clinical Study

Who this might be right for
Breast Cancer
The First Affiliated Hospital with Nanjing Medical University 102
Large-scale testing (Phase 3)Study completedNCT03337724
What this trial is testing

Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer

Who this might be right for
Breast Cancer
Hoffmann-La Roche 579
Testing effectiveness (Phase 2)Study completedNCT03809013
What this trial is testing

A Open-label, Single-arm, Multicenter, Phase II Study of RC48-ADC to Evaluate the Efficacy and Safety of Subjects With HER2 Overexpressing Locally Advanced or Metastatic Urothelial Cancer

Who this might be right for
Urothelial Carcinoma
RemeGen Co., Ltd. 64
Large-scale testing (Phase 3)UnknownNCT03500380
What this trial is testing

RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver Metastases

Who this might be right for
Breast NeoplasmsBreast DiseasesCapecitabine+3 more
RemeGen Co., Ltd. 301
Testing effectiveness (Phase 2)Study completedNCT04300790
What this trial is testing

Study to Evaluate the Effect of Metformin in the Prevention of HG in HR[+]/HER2[-] PIK3CA-mut Advanced BC Patients

Who this might be right for
Breast Cancer
MedSIR 69
Testing effectiveness (Phase 2)WithdrawnNCT01479179
What this trial is testing

Trastuzumab in Combination With AMG 479 in HER-2 Overexpressing MBC Progressing on Trastuzumab

Who this might be right for
Breast Cancer
M.D. Anderson Cancer Center
Next Page